Clinical Trial Update: Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating cetuximab in combination with chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck has completed. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2012-08-10